The Senior Director, Compliance will support the Vice President, Compliance to implement and continuously enhance a comprehensive compliance program that spans healthcare, research, manufacturing, export controls, economic sanctions, trade and tariff-related compliance, general corporate compliance and other global business conduct requirements applicable to a growing multinational organization. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.